At the Consortium of Multiple Sclerosis Centers (CMSC) 2026 Annual Meeting, researchers unveiled highly anticipated 3-year results from the phase 2 open-label extension of frexalimab, an investigational treatment for relapsing multiple sclerosis (RMS). (Pharmacy Times) - May 28, 2026 - "The clinical outcomes were equally robust. In the group receiving 1200 mg intravenously (IV), 86% of participants remained relapse-free over 3 years. The adjusted annualized relapse rate (ARR) for this group was remarkably low at 0.11. Furthermore, participants’ physical disability levels, measured by the Expanded Disability Status Scale, remained stable through week 144...A key focus of the presentation was frexalimab’s safety profile, particularly its impact on the immune system. Because the drug does not deplete lymphocytes, mean lymphocyte counts remained stable over the 144-week duration. Additionally, levels of protective antibodies—immunoglobulin G (IgG) and M (IgM)—showed stability or only marginal decreases, which is a significant finding for long-term immune health."
P2 data • Immunology • Multiple Sclerosis
|